Pathological basis for neurotransmitter changes in Parkinson's disease.
about
β1-Adrenergic receptors activate two distinct signaling pathways in striatal neuronsBehavioral and neurophysiological correlates of striatal dopamine depletion: a rodent model of Parkinson's disease.Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's diseaseAlterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease.Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistryCortical Lewy body dementia: clinical features and classification.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Postmortem locus coeruleus neuron count in three American veterans with probable or possible war-related PTSD.Noradrenaline and Parkinson's disease.Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.Amine accumulation: a possible precursor of Lewy body formation in Parkinson's disease.Proof of principle: Transformation approach alters caudate nucleus volume and structure-function associations.Effects of Antidepressants on DSP4/CPT-Induced DNA Damage Response in Neuroblastoma SH-SY5Y Cells.Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degenerationConceptualization of depression in Parkinson's diseaseAnatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.Parkinsonian Balance Deficits Quantified Using a Game Industry Board and a Specific Battery of Four Paradigms.Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder.The serotonergic system in motor and non-motor manifestations of Parkinson's disease.Neurotoxin-induced DNA damage is persistent in SH-SY5Y cells and LC neurons.The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy.The relationship of the reticular system to the primary pathoetiology of Parkinson's disease.Reversal of visual neglect in Parkinson's disease by treatment with picoTesla range magnetic fields.Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys.Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease.Monoaminergic Modulation of Motor Cortex Function.Rapid improvement of visuoperceptive functions by picoTesla range magnetic fields in patients with Parkinson's disease.Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus.Early versus late-onset Parkinson's disease: the role of the locus coeruleus.Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis
P2860
Q28581364-4ECB40FA-BAF0-43FF-9320-B6C778360085Q30395768-95C9CC5F-02DB-4582-A1F6-9379D40409F4Q33591546-3DE5A55D-EA7F-4CD7-82B7-C53B938D3F9AQ33619721-B61526A1-D4B6-4DC5-A366-CBE6DEFF0E50Q33627585-F5287FD9-8D91-4446-9265-6E295D09CB5FQ33629696-4459FFF5-3317-43D7-97D0-CDCB6ED18B20Q34307633-8B59AB2B-9AB8-4FCC-89D2-30A5F87BCF96Q34480998-86B211AF-33E0-4226-BEF7-15A900E0A655Q35013240-8F8E7C47-3DB4-4EDE-A4C3-1E6431731C8EQ35018088-E11BEA49-6DAA-4DB3-9470-69582B7F9D86Q35222898-A42C9C4D-E19A-42BB-9924-2427404B7D34Q35634769-6D1D45C9-A793-44F7-84B1-441533BDAC7AQ35812335-9D655B5B-DF40-4D9A-BE51-DE19199606DAQ36691830-AAF6F196-70BF-4A4D-A377-CD0F3839FF99Q36700296-EEBA617A-1E8B-4E93-8F8A-3DF01B9B0CA0Q36947501-9C1F1B32-97D8-4E0A-96DD-87C7DED89BF8Q37214996-9644EC2E-A339-4371-9984-6FF2A6065207Q37231121-976C585B-CD56-416B-AC17-DA0B8CEB9B40Q38118061-2A4ACB32-640E-46E5-A886-9CCC84916CB6Q38905310-116706B9-270D-440A-8345-8E361F0CC557Q39108546-84CED1FF-7207-43F4-85B3-9C4B46FF923CQ39551939-212844D6-4D02-49D7-92D4-30DE727C5358Q40727514-3B0B38A2-5DA8-4D82-80B7-2652AC6F094BQ40945102-AFC5DCCA-4792-48CB-BFBD-F4EBB44990BBQ42483704-0510AAE0-EDED-4E1D-91BF-89A9C65C83FEQ43778565-2E77F9B7-CD26-4919-B472-1867E49B69BEQ44523798-1F35A221-D03B-49B5-9906-100916A7CD06Q48280336-20EA7A43-4C0E-45D6-AB6F-86411957B757Q48402405-AC88EBEC-B48A-4DCB-A263-3EC42141ECA0Q48685237-FB80BE1E-3DCE-40CC-885C-081B4AFBADD6Q48958708-9FC5864A-C1B5-4407-BAB6-C39067ABD4B2Q52148846-7A9EE2CD-E4C6-49C5-8DA1-4926C2628957Q58750079-D938D908-185C-40B9-AE7D-B3220D052A3F
P2860
Pathological basis for neurotransmitter changes in Parkinson's disease.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh-hant
name
Pathological basis for neurotransmitter changes in Parkinson's disease.
@en
Pathological basis for neurotransmitter changes in Parkinson's disease.
@nl
type
label
Pathological basis for neurotransmitter changes in Parkinson's disease.
@en
Pathological basis for neurotransmitter changes in Parkinson's disease.
@nl
prefLabel
Pathological basis for neurotransmitter changes in Parkinson's disease.
@en
Pathological basis for neurotransmitter changes in Parkinson's disease.
@nl
P2860
P1476
Pathological basis for neurotransmitter changes in Parkinson's disease.
@en
P2093
P2860
P356
10.1111/J.1365-2990.1983.TB00320.X
P577
1983-01-01T00:00:00Z